UBS reiterates Abercrombie & Fitch stock rating on growth outlook

UBS reiterated a Buy on Abercrombie & Fitch (ANF) and lifted its price target to $153 (from $136), arguing brands are strengthened for growth beyond FY2026. UBS projects a 7-cent Q2 EPS beat on better-than-expected sales and gross margin and expects ANF to raise FY2026 EPS guidance from $10.20 to $11.00 toward the high end, though it sees limited near-term upside given the stock’s ~9.5x forward FY2 P/E. The article also cites mixed positioning—Barclays upgraded to Equalweight on improved FY2026 tariff outlook and better promotions, while Morgan Stanley resumed coverage at Equalweight but expects 2026 EPS ~9% below consensus—plus ongoing strategic options for ANF’s China unit that could be worth several hundred million dollars.

Analysis

ANF’s near-term setup looks more like a quality-consumer holding pattern than a clean chase. The core mechanism is not just top-line resilience; it’s that fuller-price selling and mix are translating into operating leverage, which should keep consensus FY26 EPS drifting higher and support a modest multiple re-rate if comps stay positive. That said, at under 10x forward two-year earnings, the market is already discounting a lot of the margin story, so the immediate post-print upside is likely capped unless management gives explicit evidence that second-half demand is still accelerating.

The competitive read-through matters: if ANF continues to defend price, peers with more promotional exposure and weaker brand heat should feel the pressure first, especially in mall-led specialty retail. A sustained ANF outperformance would also signal that the category is still taking share from broader discretionary spending rather than merely benefiting from a temporary fashion cycle, which is a negative for lower-quality apparel names and a neutral-to-slightly-negative read for general retail traffic proxies.

The bigger catalyst path is 1-3 months, not days: guidance optics, tariff assumptions, and any China-unit monetization. A structured sale or JV would be additive if proceeds are used for buybacks, but if the asset is spun as “strategic review” without economics, the market may ignore it. The contrarian risk is that consensus is underestimating how hard back-half comparisons get; if margin/comp momentum slows even modestly, the multiple can compress faster than EPS grows. Falsifier: a guide below the high end of FY26 EPS or any sign gross margin is reverting via markdowns/tariff pass-through.

Key Decisions for Investors

• Do not chase ANF into the report; wait for a post-earnings pullback of 5-8% and use it to initiate a 1-3 month long if management confirms FY26 EPS at or above the high end of guidance.
• Pair trade: long ANF / short AEO for 1-3 months to express brand-strength divergence and better pricing power; stop if ANF guide or comp commentary softens materially versus peers.
• If already long ANF, consider selling near-dated upside against the position ahead of the next print; the market appears to be pricing the beat and guide raise, limiting immediate upside.
• Watch China-unit process as a medium-term catalyst, not a core thesis driver; only add on confirmation of cash proceeds, valuation, and buyback intent.